Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Buscarini, Elisabetta, Botella, Luisa Maria, Geisthoff, Urban, Kjeldsen, Anette D., Mager, Hans Jurgen, Pagella, Fabio, Suppressa, Patrizia, Zarrabeitia, Roberto, Dupuis-Girod, Sophie, Shovlin, Claire L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360670/
https://www.ncbi.nlm.nih.gov/pubmed/30717761
http://dx.doi.org/10.1186/s13023-018-0982-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360670/
https://www.ncbi.nlm.nih.gov/pubmed/30717761
http://dx.doi.org/10.1186/s13023-018-0982-4

Ejemplares similares